Psoriatic arthritis
New effective treatments for people with psoriatic arthritis revealed at conference
Two new drugs could soon be available for people with psoriatic arthritis thanks to promising data presented at the Annual European Congress of Rheumatology. Continue reading
A diagnosis of psoriatic arthritis led Pam Relph from the army to the Paralympics, just in time to win gold (twice)
Pam Relph’s heartbreak when she was medically discharged from the army due to psoriatic arthritis was rapidly followed by elation at finding herself on the British Paralympic rowing team, training for the 2012 London Paralympic Games. Continue reading
Longer-lasting pain relief thanks to compound – new developments
Experts are developing compounds that could allow the pain-relieving effects of ibuprofen to last longer, they report in Molecular Pharmaceutics. And the approach could also be used to deliver other drugs orally that currently can only be taken intravenously.
Metal-organic frameworks are compounds made of metal ions linked to organic ligands, for drug delivery. Active ingredients can be packed inside the metal organic frameworks. They are porous, and some dissolve in water so are good candidates for drug couriers.
The researchers loaded ibuprofen into metal organic frameworks. The compounds were found to reach the bloodstream (of mice) quickly and lasted for twice as long as ibuprofen salts, which are the active ingredient in liquid gel formulations.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.
Psoriatic arthritis linked with diabetes and other endocrine disorders
Psoriatic arthritis is linked to diabetes, Cushing disease, hypothyroidism and osteoporosis, according to a recent analysis in The Journal of Rheumatology. Continue reading
First Humira biosimilar approved in Europe
The European Commission has approved Amgevita, a biosimilar to adalimumab (Humira), for all of its available indications. Continue reading